LT3606928T - Makrociklinis junginys ir jo panaudojimo būdai - Google Patents

Makrociklinis junginys ir jo panaudojimo būdai

Info

Publication number
LT3606928T
LT3606928T LTEPPCT/US2018/025887T LT18025887T LT3606928T LT 3606928 T LT3606928 T LT 3606928T LT 18025887 T LT18025887 T LT 18025887T LT 3606928 T LT3606928 T LT 3606928T
Authority
LT
Lithuania
Prior art keywords
macrocyclic compound
macrocyclic
compound
Prior art date
Application number
LTEPPCT/US2018/025887T
Other languages
English (en)
Lithuanian (lt)
Inventor
Yoshito Kishi
Kazunobu Kira
Ken Ito
Original Assignee
President And Fellows Of Harvard College
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by President And Fellows Of Harvard College, Eisai R&D Management Co., Ltd. filed Critical President And Fellows Of Harvard College
Publication of LT3606928T publication Critical patent/LT3606928T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEPPCT/US2018/025887T 2017-04-05 2018-04-03 Makrociklinis junginys ir jo panaudojimo būdai LT3606928T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (1)

Publication Number Publication Date
LT3606928T true LT3606928T (lt) 2022-12-12

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/025887T LT3606928T (lt) 2017-04-05 2018-04-03 Makrociklinis junginys ir jo panaudojimo būdai

Country Status (34)

Country Link
US (2) US11725015B2 (https=)
EP (2) EP4119563A3 (https=)
JP (4) JP7168580B2 (https=)
KR (2) KR102836514B1 (https=)
CN (2) CN110831946B (https=)
AU (2) AU2018250147B2 (https=)
CA (1) CA3056945A1 (https=)
CL (1) CL2019002854A1 (https=)
CO (1) CO2019011538A2 (https=)
DK (1) DK3606928T3 (https=)
EC (1) ECSP19075677A (https=)
ES (1) ES2931533T3 (https=)
HR (1) HRP20221385T1 (https=)
HU (1) HUE060466T2 (https=)
IL (2) IL288991B2 (https=)
JO (1) JOP20190234B1 (https=)
LT (1) LT3606928T (https=)
MA (1) MA48027B1 (https=)
MD (1) MD3606928T2 (https=)
MX (1) MX389899B (https=)
NZ (2) NZ757372A (https=)
PE (1) PE20200602A1 (https=)
PH (1) PH12019502197A1 (https=)
PL (1) PL3606928T3 (https=)
PT (1) PT3606928T (https=)
RS (1) RS63755B1 (https=)
SA (1) SA519410259B1 (https=)
SG (1) SG11201908603PA (https=)
SI (1) SI3606928T1 (https=)
SM (1) SMT202200455T1 (https=)
TW (3) TWI781163B (https=)
UA (1) UA124399C2 (https=)
WO (1) WO2018187331A1 (https=)
ZA (1) ZA201906279B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SMT202200455T1 (it) * 2017-04-05 2023-01-13 Harvard College Composto macrociclico e relativi usi
WO2019010363A1 (en) * 2017-07-06 2019-01-10 President And Fellows Of Harvard College HALICHONDRINES SYNTHESIS
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CN101657990B (zh) 2007-03-07 2014-03-19 交互数字技术公司 用于产生和处理MAC-ehs协议数据单元的方法和设备
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
CN101910180A (zh) 2007-11-16 2010-12-08 卫材R&D管理有限公司 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
WO2012096926A2 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
CA2860446C (en) 2011-12-29 2017-01-10 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
SG11201404432QA (en) * 2012-11-30 2014-10-30 Hangzhou Zylox Pharma Co Ltd Rafamycin analogs and methods for making same
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
BR112016009452B1 (pt) 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
EP3077399B1 (en) 2013-12-06 2019-02-20 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin b analogs
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
US10562859B2 (en) * 2015-07-01 2020-02-18 Signalchem Lifesciences Corporation Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
EP3582804A1 (en) 2017-02-20 2019-12-25 Polyphor Ag Pharmaceutical combinations for treating cancer
SMT202200455T1 (it) * 2017-04-05 2023-01-13 Harvard College Composto macrociclico e relativi usi
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
WO2019010363A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College HALICHONDRINES SYNTHESIS
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
WO2022019921A1 (en) 2020-07-24 2022-01-27 President And Fellows Of Harvard College Ketone synthesis and applications

Also Published As

Publication number Publication date
EP4119563A3 (en) 2023-04-05
JP2020513021A (ja) 2020-04-30
EP3606928B1 (en) 2022-09-07
JP7400025B2 (ja) 2023-12-18
JP7696416B2 (ja) 2025-06-20
AU2022291454A1 (en) 2023-02-16
JP2024028872A (ja) 2024-03-05
TW202321259A (zh) 2023-06-01
JP6366873B1 (ja) 2018-08-08
JOP20190234A1 (ar) 2019-10-03
SI3606928T1 (sl) 2023-02-28
RS63755B1 (sr) 2022-12-30
WO2018187331A8 (en) 2018-12-06
BR112019020208A2 (pt) 2020-04-22
JP2022153392A (ja) 2022-10-12
MX389899B (es) 2025-03-20
IL288991B2 (en) 2023-12-01
TWI863657B (zh) 2024-11-21
PT3606928T (pt) 2022-12-05
PE20200602A1 (es) 2020-03-10
TWI781163B (zh) 2022-10-21
US11725015B2 (en) 2023-08-15
KR20190137121A (ko) 2019-12-10
MX2019011982A (es) 2019-11-08
DK3606928T3 (da) 2022-11-28
KR102836514B1 (ko) 2025-07-22
US12421248B2 (en) 2025-09-23
CO2019011538A2 (es) 2020-02-28
IL269788B (en) 2022-01-01
JOP20190234B1 (ar) 2023-09-17
EP4119563A2 (en) 2023-01-18
CN115093429A (zh) 2022-09-23
CN110831946A (zh) 2020-02-21
TW201902902A (zh) 2019-01-16
NZ798392A (en) 2026-03-27
CL2019002854A1 (es) 2019-12-27
SA519410259B1 (ar) 2022-09-11
KR102634732B1 (ko) 2024-02-13
SG11201908603PA (en) 2019-10-30
MA48027B1 (fr) 2022-12-30
AU2018250147B2 (en) 2022-09-29
IL288991A (en) 2022-02-01
IL288991B1 (en) 2023-08-01
MD3606928T2 (ro) 2022-12-31
HUE060466T2 (hu) 2023-03-28
WO2018187331A1 (en) 2018-10-11
UA124399C2 (uk) 2021-09-08
HRP20221385T1 (hr) 2023-01-06
RU2019135531A3 (https=) 2021-09-07
CN115093429B (zh) 2024-08-30
PH12019502197A1 (en) 2020-12-07
JP7168580B2 (ja) 2022-11-09
ES2931533T3 (es) 2022-12-30
ECSP19075677A (es) 2020-01-31
RU2019135531A (ru) 2021-05-05
AU2022291454B2 (en) 2024-03-28
US20210261566A1 (en) 2021-08-26
ZA201906279B (en) 2021-01-27
CN110831946B (zh) 2022-06-21
JP2018177774A (ja) 2018-11-15
CA3056945A1 (en) 2018-10-11
SMT202200455T1 (it) 2023-01-13
TW202426457A (zh) 2024-07-01
AU2018250147A1 (en) 2019-10-03
PL3606928T3 (pl) 2023-02-06
TWI836643B (zh) 2024-03-21
KR20240023674A (ko) 2024-02-22
IL269788A (en) 2019-11-28
NZ757372A (en) 2026-03-27
US20230406863A1 (en) 2023-12-21
EP3606928A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
SG11202000356VA (en) Macrocyclic compounds and uses thereof
IL273236A (en) Pyrazolopyrimidine compounds and their uses
GB201708652D0 (en) Novel compounds and uses
IL288991A (en) A macrocyclic compound and its uses
GB201714745D0 (en) New compounds and uses
IL272808B (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
GB201616439D0 (en) Compounds and uses
SG11202105125XA (en) Macrocyclic compound and use thereof
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
GB201614224D0 (en) Compounds and uses thereof
GB201810121D0 (en) Macrocyclic compounds and uses thereof
HK40032561A (en) Macrocyclic compounds and uses thereof
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses
GB201715210D0 (en) Macrocyclic compounds
GB201704121D0 (en) Macrocyclic compounds
GB201704125D0 (en) Macrocyclic Compounds
GB201602572D0 (en) New compound and uses